Xarelto

Xarelto (the trade name for Rivaroxaban) promises relief to patients who suffer from blood clots, whether those clots are caused by hip and knee replacements, or they stem from atrial fibrillation, deep vein thrombosis, or pulmonary embolus. The drug, marketed by Bayer Pharmaceuticals and Janssen, a division of Johnson & Johnson, was approved for sale by the Food & Drug Administration in 2011. In 2012, the drug was subjected to a clinical trial for people with acute coronary syndrome (“ACS”). An FDA advisory committee found that this powerful anticoagulant heightened the risk for abnormal bleeding and recommended against expanding its uses. Since then, Xarelto has been linked to serious side effects that include internal bleeding and hemorrhagic stroke.

Xarelto also may interact with other medications, including other blood thinners (such as Warfarin and Plavix), aspirin and ibuprofen, heart medications, HIV medications, anti-seizure drugs, and antibiotics. Further, until May 2018, seven years after Xarelto’s initial approval, there is no antidote to the internal bleeding that the drug caused. That meant that the drug could trigger internal bleeding and, for seven years, there was no antidote to that potentially lethal side effect. Since 2014, Xarelto has been the subject of thousands of lawsuits alleging that Bayer and Janssen failed to warn patients of the seriousness of the risks posed by the drug and that the companies withheld vital information about the drug’s safety (including the lack of a viable antidote). If you or someone you love has suffered adverse health events after using Xarelto, GetLegal has the tools and resources to help you find skilled legal representation to protect your rights. Visit our attorney directory, look for your geographic location and find the best lawyer for your situation.

Last updated December 12, 2018